Despite the impact of the COVID-19 pandemic, investment and interest in clinical trials of potential new treatments for Parkinson’s disease remains strong, according to a report. The study suggests that the landscape of developmental Parkinson’s treatments has changed little over the last year, with researchers noting a slight increase in the proportion of disease-modifying treatments under early investigation. “The main take away from the analysis is that there is a very rich pipeline of novel therapies…

You must be logged in to read/download the full post.